Sanofi reports positive asthma study data for dupilumab

Sanofi and Regeneron have announced new clinical trial data that demonstrates the potential benefits offered by dupilumab in the treatment of asthma.

Results from the phase III LIBERTY ASTHMA QUEST study of dupilumab, which involved a broad population of patients with uncontrolled persistent asthma, showed that the drug was able to meet its two primary endpoints.

When added to standard therapies, dupilumab reduced the rate of severe asthma attacks and improved lung function after 52 weeks of treatment, while the overall rates of adverse events, were comparable between the dupilumab and placebo groups.

This trial enrolled 1,902 patients – including 1,795 adults and 107 adolescents – across 413 study sites worldwide. Data from this study will be used to support a supplemental biologics licence application that will be submitted to the US Food and Drug Administration by the end of this year.

Dr Elias Zerhouni, president of global research and development at Sanofi, said: "We will work diligently with health authorities to bring this new application of dupilumab to the patients who most need it."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.